Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4B | O94953 | 3/20 | 0.42 |
| ▸ | KDM5C | P41229 | 3/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27096820 | 0.80 | KDM4B (0.46) | KDM4BKDM5CKDM5BKDM4ACCR1 | |
| SCHEMBL824559 | 0.77 | CCR1 (0.36) | CCR1CCR5CCR8NR4A1KDR | |
| SCHEMBL11958452 | 0.77 | FEN1 (0.37) | CCR1CCR5CCR8NR4A1KDR | |
| SCHEMBL29834811 | 0.77 | ASIC3 (0.49) | NR4A1ALDH1A1 | |
| SCHEMBL11958462 | 0.76 | CCR1 (0.35) | CCR1CCR5CCR8NR4A1KDR | |
| SCHEMBL14031589 | 0.76 | SCN9A (0.35) | CCR1CCR5CCR8NR4A1KDR | |
| SCHEMBL29834758 | 0.76 | NR4A1 (0.41) | NR4A1KDRALDH1A1MAPK14 | |
| SCHEMBL2030061 | 0.75 | PIM1 (0.40) | KDR | |
| SCHEMBL1137172 | 0.75 | NOS3 (0.50) | NR4A1ALDH1A1MAPK14 | |
| SCHEMBL5058569 | 0.75 | LTA4H (0.41) | CCR1CCR5CCR8NR4A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | KDM4B 3297/4885KDM5C 2554/4885KDM5B 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.